ECCT Modulates the Therapeutic Landscape for Advanced Lung Adenocarcinoma: A Case Series Demonstrating Efficacy Across EGFR-Mutant and Wild-Type Subtypes

Electro-Capacitive Cancer Therapy (ECCT), a non-invasive electric-field–based treatment used alongside standard therapies, showed meaningful benefits in a case series of six patients with advanced lung adenocarcinoma, including both EGFR-mutant and EGFR-wild-type profiles. Across the cohort, five patients experienced partial tumor response and one achieved stable disease, with imaging demonstrating notable tumor regression and improved clinical condition. ECCT was well tolerated with no severe adverse events, even when combined with chemotherapy, immunotherapy, radiotherapy, or targeted EGFR-TKI treatments. These results indicate that ECCT may enhance the effectiveness of conventional treatments across molecular subtypes while maintaining a favorable safety profile. Conclusion: This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes.